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Introduction
Tetrathiomolybdate (TM) was first developed as an anticopper drug for the treatment of neurological symptoms in patients with Wilson's disease (Brewer et al., 1991) . Because of its fast action and low toxicity, TM may prove to be a useful drug for the initial treatment of Wilson's disease. Subsequently, it was found to have anticancer, antiinflammatory, antifibrotic, and immune mediating effects.
TM was shown to have anticancer effects in both tumor models (Cox et al., 2003; Pan et al., 2002) and a phase I clinical study (Brewer et al., 2000) . One mechanism for the anticancer effects is through inhibition of angiogenesis (Lowndes and Harris, 2005) , with copper serving as an important cofactor for angiogenesis. Many proangiogenic cytokines, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and IL-8, are copper dependent (Pan et al., 2002) . One mechanism of suppression of cytokine signaling is through inhibition of nuclear factor kappa B (NF-κB) (Pan et al., 2002) . Based on its antiangiogenic property, TM was determined to be an effective treatment in retinal neovascularization (Elner et al., 2005) .
Antifibrotic effects of TM were also observed in bleomycin-induced pulmonary fibrosis and carbon tetrachloride-induced cirrhosis mouse models (Askari et al., 2004) . Both studies showed that TM protected against fibrosis by inhibition of TGF-β, the key cytokine in fibrogenesis.
In some other animal experiments, TM was shown to protect against liver injury induced by concanavalin A (Con A) (Askari et al., 2004) and acetaminophen (Ma et al., 2004) , and heart injury induced by doxorubicin in mice (Hou et al., 2005) . In these This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 25, 2008 as DOI: 10.1124 at ASPET Journals on April 27, 2017 jpet.aspetjournals.org Downloaded from JPET #131227 6 studies, levels of the inflammatory cytokines, TNF-α and IL-1β, were significantly decreased by TM treatment.
TM was also shown to have protective effects in autoimmune disease animal models, including a type І diabetes model in non-obese diabetic mice , an autoimmune arthritis model (Omoto et al., 2005; McCubbin et al., 2006 ) and a Con A autoimmune hepatitis model (Askari et al., 2004) .
The mechanism of action of TM involves forming a stable tripartite complex with copper and protein which is unavailable for cellular uptake (Mills et al., 1981) . Given with food, TM binds copper in food and endogenously secreted copper with protein in the alimentary tract, and prevents copper absorption. Given away from food, TM is absorbed into the blood and complexes free copper with plasma albumin. This complex is primarily degraded in the liver, with copper excretion in the bile.
Copper is an essential trace element for many biological processes. It serves as a cofactor for a number of enzymes, such as cytochrome oxidase, SOD1, metallothionein and several transcription factors (Linder and Hazegh-Azam, 1996) . Generally, copper is taken up into hepatocyte and incorporated into ceruloplasmin in the Golgi apparatus, and then secreted into the serum as holoceruloplasmin, a mature form of ceruloplasmin (Murata et al., 1995) . Because the synthesis of ceruloplasmin is directly regulated by the bio-availability of copper to the liver, it is a good surrogate marker of body copper status.
The copper in ceruloplasmin accounts for about 90% of the total plasma copper (Goodman et al., 2004) . Because 80% of the copper leaving the liver is excreted via the bile, biliary excretion represents the major pathway of copper elimination (Luza and Speisky, 1996) . Excessive copper accumulation in the liver secondary to cholestasis has This article has not been copyedited and formatted. The final version may differ from this version. (Deering et al., 1977) .
Copper levels are also elevated in a variety of other clinical and experimental liver diseases, probably due to impaired excretion (Togashi et al., 1992; Ebara et al., 2003) .
The present study investigated the potential use of TM in an animal model of hepatic cholestasis. The working hypothesis is that the hepatic fibrotic pathway is modulated by copper . Our objective was to test the potential protective effects of TM in a BDL mouse model of hepatic fibrosis.
This article has not been copyedited and formatted. The final version may differ from this version. George Brewer, University of Michigan, Ann Arbor, Michigan) was dissolved in deionized water. In TM-treated animals, it was given in a daily dose of 0.9 mg per mouse by means of intragastric gavage, beginning 5 days before BDL. Mice were fed a low copper diet (Harlan Teklad, Madison, WI) with copper content of 2 mg/kg.
Bile duct ligation was performed using a standard technique (Uchinami et al., 2006) .
Briefly, mice were anesthetized with ketamine and xylazine. After midline laparotomy, the common bile duct was exposed and twice ligated with 6-0 silk suture. Sham operation was performed by gently touching the bile duct. The abdomen was closed in layers, and the animals were allowed to recover on a heat pad. All the animals were killed five days after surgery, and blood and liver samples were harvested.
Copper Status
This article has not been copyedited and formatted. The final version may differ from this version. Ceruloplasmin was used as a surrogate marker of copper status because the liver secretes ceruloplasmin into the blood in an amount that depends on copper availability (Hou et al., 2005) , and was measured on the basis of its oxidase activity (Schosinsky et al., 1974) in blood from retro-orbital sinus bleeding.
Liver Enzyme Assay
Plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ -glutamyl transpeptidase (γ-GTP), and total bilirubin assays were performed using commercially available kits (Infinity, Thermo Electron Corp., Melbourne, Australia) based on a colorimetric method.
Cytokine Assay
Plasma TNF-α and TGF-β1 levels were determined using commercial ELISA kits (BioSource, Camarillo, CA) according to manufacturer's instructions.
Histology and Immunohistochemistry
Formalin-fixed, paraffin-embedded liver sections were cut at 3 µm thickness using a routine procedure. Liver injury was determined by staining with Masson's trichrome.
Extracellular matrix accumulation in liver sections was determined by staining with Sirius red-fast green (Lopez-De Leon and Rojkind, 1985) . JPET #131227 10 pooled to determined means. Image analysis was performed using techniques described previously (Bergheim et al., 2006) .
For immunohistochemical analysis, sections were incubated with anti-α-SMA
(1/1000, DAKO, Carpenteria, CA), for 30 min. Staining was visualized using the horseradish peroxidase-conjugated DAKO staining system (DAKO InVision, Carpenteria, CA).
Isolation of RNA and Real Time RT-PCR
Total RNA was extracted from liver tissues using TRIZOL (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. For real-time RT-PCR, the first-strand cDNA was synthesized using TaqMan Reverse transcription reagents (Applied Biosystems, Foster City, CA). The reverse transcription was carried out using 1×Taqman RT buffer, Reactions in which the enzyme or RNA were omitted were used as negative controls.
Real-time PCR was performed with an ABI prism 7500 sequence detection system and SYBR green I dye reagents. Primers were designed by Primer Express Software Version 3.0 (Applied Biosystems, Foster City, CA) ( Table 1 ). The parameter Ct (threshold cycle) was defined as the fraction cycle number at which the fluorescence passed the threshold.
The relative gene expression was analyzed using 2 -∆∆Ct method (Livak and Schmittgen, 2001 ) by normalizing with GAPDH gene expression in all the experiments.
Western Blot
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Hepatic Lipid Peroxidation and GSH/GSSG Assay
Lipid peroxidation was assessed by measuring MDA and 4-HAE using commercial kits (Oxford Biomedical Research, Oxford, MI). Reduced glutathione (GSH) and oxidized glutathione (GSSG) were determined by HPLC as described previously (Richie and Lang, 1987) .
Statistical Analysis
Results are expressed as mean ± SEM. Statistical analysis was performed using oneway ANOVA followed by Tukey's multiple comparison test. P < 0.05 was considered statistically significant.
Results
Copper Status
The plasma ceruloplasmin level was significantly elevated (approximately five fold)
in the mice five days after BDL. The mean ceruloplasmin level in TM-treated BDL animals was markedly lower than that of animals with BDL alone (about 20% of BDL).
( 
TM Attenuated Cholestatic Liver Injury Induced by BDL
Liver injury was assessed by plasma levels of liver enzymes (ALT, AST, γ -GT and ALP), total bilirubin, liver/body weight ratio and histology. As expected, after five days, BDL significantly increased plasma levels of these enzymes and total bilirubin compared with sham-operated animals (Fig.2) . These parameters were within normal ranges in both
sham-operation and sham-operation plus TM-treated mice. The increase in plasma ALT, γ -GT, ALP and total bilirubin caused by BDL was significantly reduced by 30%-34% in TM-treated BDL mice. Liver/body weight ratio in TM-treated BDL mice was also significantly lower than that of BDL mice, suggesting that tissue remodeling was more effective in TM-treated mice compared to untreated BDL mice (Fig.2 ).
Masson's Trichrome staining showed extensive bile infarcts, which are confluent foci of hepatocyte feathery degeneration due to bile acid cytotoxicity, bile duct proliferation and bridging fibrosis in untreated BDL mice (Fig.3C ). All these lesions were markedly attenuated in TM-treated BDL mice (Fig.3D) . No pathological changes were observed in liver tissues from mice with sham operation and sham operation plus TM (Fig.3A, B) .
TM Attenuated Increased Plasma TNF-α and TGF-β1 Levels Induced by BDL
Plasma inflammatory and fibrogenic cytokines, TNF-α and TGF-β1, which play important roles in the activation of hepatic stellate cells, were significantly increased by 4-fold and 2-fold after five days BDL (Fig.4) . However, both TNF-α and TGF-β1 production were significantly blunted in TM-treated BDL mice compared with untreated BDL mice. TNF-α was decreased by 35% in TM-treated BDL mice. TGF-β1 production was almost completely blocked compared to control level, suggesting that TM may This article has not been copyedited and formatted. The final version may differ from this version. 
TM Attenuated Hepatic Fibrosis Induced by BDL
Collagen content was assessed by morphometrical analysis of Sirius red staining of liver sections. Five days post BDL, the accumulation of collagen was discernible in the liver sections stained with Sirius red. In sham-operated mice livers, only normal staining around vessels was observed (Fig.5A, B) , while mild bridging fibrosis was seen in livers from BDL mice (Fig.5C ), which was markedly reduced in TM-treated BDL mice liver (Fig.5D ). Quantification of Sirius red staining by image analysis showed that collagen content was significantly increased by 2-fold in the livers of BDL mice compared to sham and sham plus TM-treated mice, and it was significantly decreased with TM treatment in BDL mice liver (Fig.5 E) .
Immunohistochemical staining for α -SMA, a marker of hepatic stellate cell activation, showed that its expression was significantly increased in the livers of mice with BDL ( Fig. 6C, D ) compared to that in sham operated mice (Fig. 6A, B) . However, it was markedly diminished in the livers of TM-treated BDL mice (Fig. 6D ) compared to BDL mice (Fig. 6C) . We further evaluated the gene expression implicated in fibrogenesis (Fig.   7 ). Real time RT-PCR data showed that the mRNA expression of TIMP-1, which inhibits collagen degradation by MMPs and protects hepatic stellate cells from apoptosis (Yoshiji et al., 2002) , was significantly up-regulated 40-fold in the livers of BDL mice, and it was decreased to 43% in TM-treated BDL mice. MMP-9, one of the members of MMP family, also called gelatinase B, is known to regulate cell matrix composition by degrading components of the extracellular matrix (Roderfeld et al., 2006 14 MMP-9 mRNA expression was significantly up-regulated 13-fold in the livers of BDL mice, and it was decreased to 37% in TM-treated BDL mice. Procollagen I α 1 mRNA expression, which encodes the major collagen type in fibrosis, increased about 11-fold in the livers of BDL mice compared to sham-operated mice, and this increase was reduced by 46% in TM-treated BDL mice, which was paralleled by a significant attenuation of liver collagen content, as assessed by Sirius red staining. PAI-1, a key regulator of fibrinolysis by plasmin (Bergheim et al., 2006) , showed a 40-fold mRNA level increase in BDL mice liver, which decreased to 62% with TM treatment.
TM Protects against Cholestatic Hepatic Injury and Fibrosis Induced by BDL May be Independent of Oxidative Stress
To evaluate the possible effects of TM on the state of oxidative stress, measurements of lipid peroxidation products, GSH/GSSG ratio, and SOD1 were carried out in liver homogenates. MDA and 4-HAE are the end products of lipid peroxidation, and can serve as markers of lipid peroxidation (Esterbauer et al., 1991) . As shown in Fig.8 , MDA and 4-HAE increased about 2-fold in the livers of BDL mice compared with sham operation mice. However, TM pretreatment did not prevent the increase of hepatic MDA and 4-HAE. GSH/GSSG ratio, which is an indicator of oxidative stress (Baron and Muriel, 1999) , significantly increased in BDL mice compared with those with sham operation, and there was no significant change with TM treatment. SOD1, one of the three eukaryotic SOD enzymes, which plays an important role in the antioxidant defense system in the liver by eliminating superoxide anion radicals (Zelko et al., 2002) , was significantly decreased in BDL mice liver compared to sham operated mice, which have abundant expression as shown by Western blot analysis (Fig. 8 bottom panel) . This
This article has not been copyedited and formatted. The final version may differ from this version. These data suggest that TM protection against hepatic injury and fibrosis induced by BDL may be independent of oxidative stress.
Discussion
TM was first introduced as an anticopper drug for the initial treatment of patients with
Wilson's disease. Later, it was found to be effective in murine models of carbon tetrachloride-induced liver fibrosis and bleomycin-induced pulmonary fibrosis. Currently, there is no ideal drug therapy for hepatic fibrosis. We postulated that copper may be important in the development/evolution of hepatic fibrosis. Our objective was to test the potential protective effects of TM in BDL mouse model. We showed that TM effectively protected against liver injury as assessed by histologic examination (Fig. 3) , and attenuated fibrosis as evaluated by Sirius red staining (Fig. 5) , α -SMA (Fig. 6 ) and fibrogenic gene expression, such as TIMP-1, MMP-9, Procollagen I α 1 and PAI-1 (Fig.   7 ). The increase in the plasma inflammatory cytokine and fibrogenic cytokine, TNF-α and TGF-β1, was markedly blocked by TM pretreatment in BDL mice, suggesting that TM can exert both anti-inflammatory and antifibrotic effects (Fig. 4) . This is consistent with previous reports in other models Askari et al., 2004) . Because TM appears to have both anti-inflammatory and antifibrotic effects, it was important to study TM in a system such as the BDL model which induces rapid hepatic fibrosis with only a modest inflammatory response. TM previously has been shown to be protective in models of liver injury which involve acute inflammation/necrosis/apoptosis such as that This article has not been copyedited and formatted. The final version may differ from this version. It currently appears that a goal of TM therapy is to maintain ceruloplasmin at midrange, which is between 20%-70% of baseline. Reducing copper to this level can inhibit some copper-containing angiogenic promoters, such as VEGF and FGF which require higher levels of copper to be active, and yet meet the basic cellular needs for copper . In this study, the copper level in BDL mice treated with TM was maintained at about 30% of that normal mouse with standard diet (ceruloplasmin 10-11mg/dL, unpublished data). Maintaining ceruloplasmin at this level was effective at attenuating liver injury and fibrosis induced by BDL. In sham-operated mice treated with TM, copper level dropped to about 15% of baseline, and weight loss was observed compared with sham-operated mice without TM therapy. However, there was no further weight loss in BDL mice treated with TM compared to untreated BDL mice.
Evidence of oxidative stress has been reported in cholestatic liver disease such as in primary biliary cirrhosis patients (Kawamura et al., 2000) and in BDL animal models (Uchinami et al., 2006; Baron et al., 1999) , and is often associated with decreased antioxidant defenses. We observed enhanced lipid peroxidation five days after BDL (Fig.   8 ). GSH/GSSG ratio, an indicator of antioxidant defenses, was significantly increased in BDL mice livers (Fig. 8) . This increase may be a compensatory response to enhanced lipid oxidation. TM treatment did not influence this glutathione response. However, SOD1, one of the oxygen radical scavenging enzymes in liver, which is copper related, was markedly suppressed after BDL, and it was partially rescued by anticopper treatment This article has not been copyedited and formatted. The final version may differ from this version. (Baron et al., 1999; Tahan et al., 2007) . A recent study by Zhong and coworkers (Zhong et al., 2002) showed that gene delivery of mitochondrial Mn-SOD (SOD2) blocked formation of oxygen radicals and TNF-α and TGF-β synthesis, thereby attenuating liver injury caused by cholestasis. However, those effects can not be attained by gene delivery of cytosolic SOD1, suggesting mitochondrial oxidative stress may be playing a role in cholestasis-induced liver injury and fibrosis.
The mechanism(s) of anticopper therapy for fibrosis remain to be elucidated. It is already known that the fibrogenic cytokines, connective tissue growth factor (CTGF) and TGF-β are copper dependent . However, how copper regulates fibrotic pathway is still unknown. It has been reported that hypoxia induced activation of hepatic stellate cells occurs through the TGF-β signaling pathway, and hypoxia-inducible factor (HIF)-1α gene expression was significantly up-regulated in cultured stellate cells in response to hypoxia (Shi et al., 2007) . HIF-1 is an ubiquitously expressed transcriptional master regulator of many genes involved in mammalian oxygen homeostasis. It was originally identified as a regulatory factor for the erythropoietin gene. Other target genes of HIF-1 are involved in iron metabolism, angiogenesis, control of blood flow, glucose uptake and glycolysis. HIF-1 also is a metal responsive transcription factor and may play an important role in metal induced carcinogenesis. HIF-1 is a α 18 subunit the regulatory component which is unique to the hypoxic response (Martin et al., 2005) . In cultured human cardiomyocytes, copper stimulated VEGF expression and angiogenesis is mediated via activating HIF-1α (Jiang et al., 2007) . Copper also has been shown to modulate HIF-1 transcriptional activity in hepatoma cells by stabilizing nuclear HIF-1α under normoxic condition (Martin et al., 2005) . In the present study, copper/ceruloplasmin levels and plasma TGF-β1 were markedly increased after BDL.
Whether high copper can induce HIF-1α expression and whether HIF-1α induces TGF-β expression and activation of hepatic stellate cells in cholestatic liver diseases require further investigation.
In summary, our data provide evidence that TM is effective at attenuating BDL induced cholestatic liver injury and fibrosis, in part by reducing TNF-α and TGF-β1. The protection may be independent of oxidative stress. The molecular mechanism(s) involving copper modulation of fibrotic pathways is an important area for future investigation and represents a potential therapeutic target for hepatic fibrosis.
This article has not been copyedited and formatted. The final version may differ from this version. All these lesions were markedly attenuated in TM-treated BDL mice (Fig.3D) . No pathological changes were observed in liver tissues with sham operation and sham+TM (Fig.3A, B ). Original magnification: ×100.
This article has not been copyedited and formatted. The final version may differ from this version. (Fig.5A, B) , only normal staining around vessels was observed, while mild bridging fibrosis was seen in livers from BDL mice (Fig.5C ), and it was markedly reduced in TM-treated BDL mice liver (Fig.5D ). Original magnification: ×100.
Quantification of Sirius red positive staining showed that collagen content in BDL+TM group is significantly decreased compared to BDL group (Fig.5 E) . There is no significant difference among BDL+TM, sham and sham+TM group. Data represent means ± SEM (n=5). *,significantly different from sham group; †, significantly different from BDL group. to that in sham operated mice (Fig.6A, B) , and it was markedly diminished in the liver of BDL mice treated with TM (Fig.6D ). Original magnification: ×100. Copper/Zinc SOD (SOD1) expression was examined by Western blot analysis using whole liver extract, and optical density of band was quantified by Image J software. A value of 1 was arbitrarily assigned to the data obtained from sham-operated mice.
MDA+4-HAE and liver GSH/GSSG ratio are significantly increased in both BDL and BDL+TM group compared to sham and sham+TM group. There is no significant difference between BDL and BDL+TM group. Data represent means ± SEM (n=5). *, significantly different from sham group.
